AKRO News and Press, Akero Therapeutics Inc. From 12/06/23

2023-12-06 18:59:01 ET Summary 89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMM...

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...

2023-12-01 17:29:51 ET Gainers: Terns Pharmaceuticals ( TERN ) +10% . Alkermes  ( ALKS ) +9% . Forrester Research ( FORR ) +7% . Amkor Technology ( AMKR ) +5% . LifeMD ( LFMD ) +4% . Losers: James River Group Holding...

2023-11-22 04:24:01 ET Summary Akero Therapeutics is a deceptively promising long at these levels. EFX still has to jump through clinical trials and has a long way to go until approval. The NASH landscape has become increasingly complex since the approval of GLP-1s and Resmeti...

2023-11-20 18:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-20 00:24:09 ET Summary Biotech stocks have been heavily impacted by rising interest rates and the disruption caused by FTC-challenging acquisitions of biotechs. The equal-weight biotech ETF (XBI) has shown signs of a rebound after a prolonged downtrend, potentially due to ...

2023-11-13 07:38:03 ET More on Akero Therapeutics Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Akero slumps leading to mixed reactions in NASH space Biggest stock movers today: Coherent, T...

-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for ...

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH 22% and 10% of patients with more advanced cirrhosis in the 50mg and 28mg dos...

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...